Clinical trials: Aripiprazole, completed
Schizophrenia
Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
Patients with schizophrenia are much more likely to be engaged in smoking and other addictive behaviors, possibly related to biochemical abnormalities in the reward center of the brain.
- Trial name
- NCT00167817
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Veterans Medical Research Foundation
Bipolar I Disorder
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder
The purpose of this study is to learn if aripiprazole is effective in the treatment of patients with acute symptoms of Bipolar Disorder.
- Trial name
- NCT00046384
- Testing
- aripiprazole
- Where
- 14 sites in United States, Argentina
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychotic Depression
The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression
The purpose of the study is to assess the safety and effectiveness of the combination of aripiprazole (Abilify) and selective serotonin reuptake inhibitors (SSRIs) in subjects with psychotic major depression.
- Trial name
- Abilify (NCT00556140)
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Healthy Volunteers
A Bioequivalence Study of ASC-01 Placebo (Aripiprazole 0 mg/Sertraline 100 mg) and Sertraline Tablet in Healthy Male Subjects
The purpose of this study is to investigate the bioequivalence of ASC-01 Placebo and sertraline Tablet in Japanese healthy male subjects.
- Trial name
- NCT02088697
- Testing
- ASC-01
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
A Study of Aripiprazole in Patients With Major Depressive Disorder
The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of aripiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy…
- Trial name
- NCT00105196
- Testing
- Aripiprazole+ ADT
- Where
- 34 sites in United States
- Volunteers
- 349 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Drug-induced Liver Injury
Rechallenge, Potential Drug Induced Liver Injury (Kaiser)
Drug re-administration or rechallenge should be avoided after drug-induced liver injury (DILI) to avoid recurrent and fatal injury. Rechallenge outcomes vary considerably by drug and patient subjects.
- Trial name
- NCT01584765
- Testing
- Prescription drugs with known hepatotoxicity
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Autism
Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children
Hypothesis: (1) Aripiprazole treatment will be superior to placebo in reducing aggression and irritability in autistic individuals as shown by reductions in the Aberrant Behavior Checklist-irritability subscale.
- Trial name
- Abilify (NCT00468130)
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Schizophrenia
Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film vs Abilify® 10 mg Tablet in Healthy Volunteers
The purpose of this study is to compare the rate and extent of absorption of Aripiprazole Oral Soluble Film 10 mg (Test) versus Abilify® 10 mg tablet (Reference) in healthy male volunteers
- Trial name
- NCT02501109
- Testing
- Aripiprazole
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- CMG Pharmaceutical Co. Ltd
First Episode Psychosis
Efficacy and Safety of Aripiprazole in First Episode Psychosis
The aim of the study is to investigate the efficacy and safety of aripiprazole in patients with first episode psychosis.
- Trial name
- NCT01026584
- Testing
- Aripiprazole
- Where
- 13 sites in South Korea
- Volunteers
- 55 people
- Sponsor
- Chonbuk National University Hospital
Schizophrenia
A Placebo-Controlled, Cross-Over Trial of Aripiprazole
This study is a ten-week, placebo-controlled, double-blind, cross-over, randomized trial of the novel antipsychotic agent, aripiprazole, added to 20 obese stable olanzapine-treated patients with schizophrenia or schizoaffective…
- Trial name
- NCT00351936
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Major Depressive Disorder
A Study of Adjunctive Aripiprazole in Participants With Major Depressive Disorder
This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive…
- Trial name
- NCT00095758
- Testing
- Antidepressant + Aripiprazole
- Where
- 28 sites in United States
- Volunteers
- 1,151 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Chronic Motor or Vocal Tic Disorder, Tourette's Disorder
Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder
The purpose of this trial is to demonstrate the efficacy and safety of aripiprazole in children and adolescents aged 6~18 years with chronic tic disorders or Tourette's disorder
- Trial name
- NCT00706589
- Testing
- aripiprazole
- Where
- 6 sites in South Korea
- Volunteers
- 61 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Autistic Disorder
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).
This study will compare the effectiveness (how well the drug works) of aripiprazole, flexibly dosed with a placebo, in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).
- Trial name
- NCT00332241
- Testing
- Aripiprazole
- Where
- 9 sites in United States
- Volunteers
- 98 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Abilify Therapy for Reducing Comorbid Substance Abuse
It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions will lead to: Reduction in the amount of alcohol and/or drugs used as measured by the…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT00208169
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Creighton University
Anesthesia, Analgesia
Impact of Aripiprazole on Postoperative Analgesia in Laparoscopic Hysterectomy
The analgesic effect of perioperative use of aripiprazole has not been fully investigated. So, this study aims to test the effects of aripiprazole versus placebo in reducing postoperative pain following laparoscopic hysterectomy…
- Conditions
- Anesthesia, Analgesia, Hysterotomy
- Trial name
- NCT05103410
- Testing
- ARIPiprazole 30 MG
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
Schizophrenia
Effect on Cognitive Function of a Treatment With Aripiprazole
To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.
- Trial name
- NCT00329810
- Testing
- Aripiprazole
- Volunteers
- 500 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Mental Disorder
Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia
To determine the safety and tolerability of multiple-dose administrations of aripiprazole intramuscular (IM) depot in the deltoid muscle in adult subjects with schizophrenia
- Conditions
- Schizophrenia, Mental Disorder, Nervous System Diseases
- Trial name
- NCT01909466
- Testing
- Aripiprazole, OPC-14597
- Where
- 11 sites in United States
- Volunteers
- 141 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients
The purpose of this study is to compare the efficacy and safety of ziprasidone and aripiprazole in hospitalized patients with schizophrenia or schizoaffective disorder
- Trial name
- NCT00634348
- Testing
- Aripiprazole, Ziprasidone
- Where
- 41 sites in United States
- Volunteers
- 256 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Alzheimer Disease
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
- Trial name
- NCT00041678
- Testing
- aripiprazole
- Where
- 6 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients
In this study, we are going to investigate quantitative and qualitative natures of appetite and eating-behavior changes induced by atypical antipsychotics, i.e., risperidone, olanzapine and aripiprazole, in schizophrenia patients.
- Trial name
- NCT01043250
- Where
- South Korea
- Volunteers
- 81 people
- Sponsor
- Samsung Medical Center